Some studies have quantified total cfDNA levels using GAPDH, beta-globin, beta2-microglobulin, hTERT, or LINE-1 as possible target genes, employing greater cfDNA levels to differentiate benign from malignant BC (27–29, 31, 32). This evidence concerns the gene HBB and breast cancer.